Thursday, June 2, 2016: 6:15 PM-8:15 PM
Exhibit Hall
Efficacy of Teriflunomide in MS Patients with a Primary Presentation of Optic Neuritis: A Subgroup Analysis of the Phase 3 TOPIC Study
Aaron E Miller, MD, Icahn School of Medicine at Mount Sinai;
Jiwon Oh, MD, St. Michael's Hospital;
Karthinathan Thangavelu, PhD, Genzyme, a Sanofi company;
Philippe Truffinet, MD, Genzyme, a Sanofi company;
Steve Cavalier, MD, Genzyme, a Sanofi company;
David Rog, MD, Greater Manchester Neurosciences Centre, Salford Royal NHS Foundation Trust
Clinical Outcomes in Patients with Faster Advancing MS Treated with Teriflunomide in TEMSO and TOWER
Aaron E Miller, MD, Icahn School of Medicine at Mount Sinai;
Ludwig Kappos, MD, University Hospital Basel;
Jiwon Oh, MD, St. Michael's Hospital;
Karthinathan Thangavelu, PhD, Genzyme, a Sanofi company;
Pascal Rufi, MD, Genzyme, a Sanofi company;
Steve Cavalier, MD, Genzyme, a Sanofi company;
Philippe Truffinet, MD, Genzyme, a Sanofi company;
Giancarlo Comi, MD, University Vita-Salute San Raffaele
Effects of Induced Depression on the Animal Model of Multiple Sclerosis: An Overlooked Disability
Amal Fuad Almahroos, BSc, College of Medicine and Medical Sciences, Arabian Gulf University;
Zahra Almosawi, BSc, College of Medicine and Medical Sciences, Arabian Gulf University;
Hawra Alalwan, BSc, College of Medicine and Medical Sciences, Arabian Gulf University;
Reem Abdulla, Bsc, College of Medicine and Medical Sciences, Arabian Gulf University;
Fajer Alammadi, BSc, College of Medicine and Medical Sciences, Arabian Gulf University;
Ahmed Al-Mahrezi, BSc, College of Medicine and Medical Sciences, Arabian Gulf University;
Ahmmed Almubarak, BSc, College of Medicine and Medical Sciences, Arabian Gulf University;
Ayman Mohamed, BSc, College of Medicine and Medical Sciences, Arabian Gulf University;
Amer Kamal, Professor, College of Medicine and Medical Sciences, Arabian Gulf University
Effect of Ocrelizumab on Humoral Immunity Markers in the Phase III, Double-Blind, Double-Dummy, IFNß-1a–Controlled OPERA I and OPERA II Studies
Amit Bar-Or, MD, FRCPC, McGill University;
Douglas L Arnold, MD, McGill University;
Giancarlo Comi, MD, University Vita-Salute San Raffaele;
Hans-Peter Hartung, MD, FRCP, FAAN, FANA, Heinrich-Heine-University Düsseldorf;
Stephen L Hauser, MD, University of California;
Fred Lublin, MD, Icahn School of Medicine at Mount Sinai;
Krzysztof Selmaj, MD, PhD, Medical University of Lodz;
Anthony Traboulsee, MD, FRCPC, University of British Columbia;
Peter Chin, MD, Genentech, Inc.;
Paulo Fontoura, MD, PhD, F. Hoffmann-La Roche Ltd.;
Hideki Garren, MD, PhD, F. Hoffmann-La Roche Ltd.;
Gaelle Klingelschmitt, MSc, F. Hoffmann-La Roche Ltd.;
Donna Masterman, MD, Genentech, Inc.;
Ludwig Kappos, MD, PhD, University Hospital Basel;
Ashley J Porter, PhD, Articulate Science
Real-World Outpatient Resource Use of Patients with Multiple Sclerosis Newly Initiating Subcutaneous Interferon ß-1a vs Oral Disease-Modifying Drugs
Chris M Kozma, PhD, CK Consulting Associates, LLC;
Frederick Munschauer, MD, EMD Serono, Inc.;
Amy L Phillips, PharmD, EMD Serono, Inc.;
Michele Springer, BA, Caudex
Cost of Patients with Multiple Sclerosis Newly Initiating Subcutaneous Interferon ß-1a Vs Oral Disease-Modifying Drugs – a Real-World Assessment
Chris M Kozma, PhD, CK Consulting Associates, LLC;
Frederick Munschauer, MD, EMD Serono, Inc.;
Amy L Phillips, PharmD, EMD Serono, Inc.;
Michele Springer, BA, Caudex
Comparison of Costs and Health Resource Utilization in Multiple Sclerosis Patients Treated with Disease-Modifying Therapies
Jacqueline Nicholas, MD, MPH, Novartis Pharmaceutical Corporation;
Aaron Boster, MD, OhioHealth Neurological Physicians;
Wei-Shi Yeh, PhD, Biogen;
Robert Garland, MS, Biogen;
Monica A Fay, PharmD, Biogen;
Ravi Iyer, PhD, Biogen;
Andrew Lee, PhD, Biogen;
Ming-Yi Huang, PhD, Biogen;
Jim B Lewin, PharmD, Biogen
≥4 Active T2 Lesions at 6 Months Predicts Future Relapse/Disability in Patients with RMS on Placebo but Not IFN ß-1a SC tiw: Post Hoc PRISMS Analyses
Anthony Traboulsee, MD, FRCPC, University of British Columbia;
Regina Berkovich, MD, PhD, University of Southern California;
Hao Zhang, PhD, EMD Serono, Inc.;
Fernando Dangond, MD, FAAN, MBA, EMD Serono, Inc.;
David Li, MD, University of British Columbia;
Michele Springer, BA, Caudex
Patients with Highly Active RRMS Despite Prior Therapy Show Durable Improvement with Alemtuzumab over 5 Years
Barry A Singer, MD, The MS Center for Innovations in Care, Missouri Baptist Medical Center;
Stephen Krieger, MD, Icahn School of Medicine, Corinne Goldsmith Dickinson Center for Multiple Sclerosis;
Regina Berkovich, MD, Keck School of Medicine, University of Southern California;
Mark S Freedman, MD, University of Ottawa and the Ottawa Hospital Research Institute;
David H Margolin, MD, PhD, Genzyme, a Sanofi company;
Karthinathan Thangavelu, PhD, Genzyme, a Sanofi company;
Aaron Boster, MD, OhioHealth Neurological Physicians
Delayed-Release Dimethyl Fumarate Does Not Adversely Affect the Pharmacokinetics of a Commonly Used Oral Contraceptive: A Drug-Drug Interaction Study
Bing Zhu, MD, PhD, Biogen;
Karin Galil, MD, MPH, Biogen;
Ivan Nestorov, PhD, Biogen;
Guolin Zhao, PhD, Biogen;
Venkata Meka, MD, Biogen;
Jeanelle Kam, MD, CPI, Covance Clinical Research Unit;
Sarah I. Sheikh, MD, Biogen;
Jim B Lewin, PharmD, Biogen
Disease Activity Is Associated with Non-Adherence in Dimethyl Fumarate Compared to Fingolimod in Clinical Practice
Carrie M Hersh, DO, MS, Cleveland Clinic;
Samuel Cohn, MD, Cleveland Clinic;
Claire Hara-Cleaver, CNP, Cleveland Clinic;
Robert Bermel, MD, Cleveland Clinic;
Robert J Fox, MD, FAAN, Cleveland Clinic;
Jeffrey A Cohen, MD, Cleveland Clinic;
Daniel Ontaneda, MD, Cleveland Clinic;
Carrie M Hersh, DO, MS, Cleveland Clinic
Evaluating Effect of Dimethyl Fumarate on Leukocytes Among Caucasian-, African- and Hispanic-American Patients with Multiple Sclerosis (MS)
Carrie L Sammarco, DNP, FNP-C, MSCN, NYU Langone;
Lana Zhovtis Ryerson, MD, New York State Multiple Sclerosis Consortium;
Lisa Laing, BSN, RN, MSCN, NYU Langone
Relapses in MS Patients Treated with DMF with No Variation in Lymphocyte Counts
Cecilie Fjeldstad, PhD, Oklahoma Medical Research Foundation;
Tania Reyna, MD, Oklahoma Medical Research Foundation;
Jennifer Smith, PA, Oklahoma Medical Research Foundation;
Tony Sharp, PA, Oklahoma Medical Research Foundation;
Gabriel Pardo, MD, Oklahoma Medical Research Foundation
A Comparative Analysis of Lymphocyte Subpopulations in Patients on Natalizumab, Fingolimod, and Dimethyl Fumarate
Christopher M Perrone, MD, University of Pennsylvania;
Eric Williamson, MD, University of Pennsylvania;
Christopher M Perrone, MD, University of Pennsylvania;
Eric Williamson, MD, University of Pennsylvania
SIRT1 as a Potential Marker of Disease Activity and Response to Treatment with Glatiramer Acetate in Multiple Sclerosis
Daniel Hewes, B.S., University of Maryland School of Medicine;
Adam Kruszewski, B.S., University of Maryland School of Medicine;
Dallas Boodhoo, B.S., University of Maryland School of Medicine;
Alexandru Tatomir, M.D., University of Maryland School of Medicine;
Vinh Nguyen, D.D.S., University of Maryland School of Medicine;
Gautam K Rao, B.S., University of Maryland School of Medicine;
Walter Royal III, M.D., Veterans Administration Multiple Sclerosis Center of Excellence;
Christopher T Bever Jr., M.D., M.B.A., University of Maryland School of Medicine;
Violeta Rus, M.D., Ph.D, University of Maryland School of Medicine;
Horea Rus, M.D., Ph.D., Veterans Administration Multiple Sclerosis Center of Excellence
RRMS Patients with an Inadequate Response to a Prior Therapy Demonstrate Slowing of Brain Volume Loss over 5 Years Following Alemtuzumab Treatment
Daniel Pelletier, MD, University of Southern California;
Gavin Giovannoni, MBBCh, PhD, Queen Mary University London, Barts and The London School of Medicine;
Douglas L Arnold, MD, McGill University;
Sven Schippling, MD, University Hospital Zurich and University of Zurich;
David H Margolin, MD, PhD, Genzyme, a Sanofi company;
Karthinathan Thangavelu, PhD, Genzyme, a Sanofi company;
Anthony Traboulsee, MD, FRCPC, University of British Columbia;
Tina Walsh, n/a, Evidence Scientific
Real-World Fingolimod First-Dose Effects in Patients with Hypertension, Cardiac Conditions and/or Receiving Selective Serotonin-Reuptake Inhibitors
Daniel Wynn, MD, Consultants in Neurology MS Center;
Chris Laganke, MD, North Central Neurology Associates;
Lesley Schofield, PhD, Novartis Pharmaceuticals Corporation;
Xiangyi Meng, PhD, Novartis Pharmaceuticals Corporation;
Nadia Tenenbaum, MD, Novartis Pharmaceuticals Corporation;
Jeremy Bright, PhD, Oxford Pharmagenesis;
Terence Smith, PhD, Oxford Pharmagenesis
Interferon ß-1a SC tiw Reduces Cumulative MRI Lesions over 24 Months in Patients with Relapsing Multiple Sclerosis: Post Hoc Analyses of PRISMS Data
David Li, MD, FRCPC, University of British Columbia;
Anthony Traboulsee, MD, FRCPC, University of British Columbia;
Eric Williamson, MD, University of Pennsylvania;
Hao Zhang, PhD, EMD Serono, Inc.;
Fernando Dangond, MD, FAAN, MBA, EMD Serono, Inc.;
Michele Springer, BA, Caudex
Can Fingolimod Reduce T1 Hypointense and Gadolium Enhancing Lesions in Hispanic MS Patients
Eduardo R Estades, MD, San Juan MS Center;
Angel Chinea, MD, San Juan Multiple Sclerosis Center;
Yatzka G Hernandez Silvestrini, MD, San Juan MS Center;
Ivonne Vicente, MD, San Juan Multiple Sclerosis Center;
Cristina Rubi, BS, San Juan Multiple Sclerosis Center;
Kenneth Stein, MD, San Juan MRI;
Eduardo R Estades, MD, San Juan MS Center;
Angel Chinea, MD, San Juan Multiple Sclerosis Center
No Evidence of Disease Activity for 4 Years Following 2 Courses of Alemtuzumab and No Further Treatment: Long-Term Responders from Care-MS II
Edward J. Fox, MD, PhD, Central Texas Neurology Consultants;
Hans-Peter Hartung, MD, FRCP, FAAN, FANA, Heinrich-Heine-University Düsseldorf;
Eva Havrdova, MD, PhD, Charles University in Prague;
Brian Steingo, MD, Fort Lauderdale Multiple Sclerosis Center;
David H Margolin, MD, PhD, Genzyme, a Sanofi company;
Karthinathan Thangavelu, PhD, Genzyme, a Sanofi company;
Gavin Giovannoni, MBBCh, PhD, Queen Mary University London, Barts and The London School of Medicine
Correlation of Clinical, MRI, and OCT Outcomes in the 11-Year Follow up from Benefit: Benefit 11
Edward J Fox, MD, Central Texas Neurology Consultants;
Gilles Edan, MD, CHU Hopital Pontchaillou;
Mark S Freedman, MD, University of Ottawa and Ottawa Hospital Research Institute;
Xavier Montalban, MD, PhD, Hospital Universitari Vall d’Hebron;
Hans-Peter Hartung, MD, FRCP, FAAN, FANA, Department of Neurology, Heinrich-Heine Universität;
Bernhard Hemmer, MD, Munich Cluster for Systems Neurology (SyNergy);
Frederik Barkhof, MD, PhD, VU University Medical Center;
Sven Schippling, MD, University Hospital Zurich;
Frederick W Foley, Ph.D., School of Psychology, Yeshiva University;
Iris-Katharina Penner, PD, COGITO Center for Applied Neurocognition and Neuropsychological Research;
Ralf Koelbach, MSc, PAREXEL International;
Dirk Pleimes, MD, Myelo Therapeutics GmbH;
Gustavo Suarez, MD, Bayer HealthCare Pharmaceuticals;
Eva-Maria Wicklein, MD, Bayer Pharma AG;
Ludwig Kappos, MD, PhD, Neurology, Departments of Medicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital Basel;
Beth Gates, BA, Precept Medical Communications;
Robert Ristuccia, PhD, Precept Medical Communications
Efficacy and Tolerability of Oral Disease Modifying Therapies in Clinical Practice
Erin E Longbrake, MD, PhD, Washington University School of Medicine;
Anne H Cross, MD, Washington University School of Medicine;
Amber Salter, PhD, Washington University in St. Louis;
Erin E Longbrake, MD, PhD, Washington University School of Medicine
Efficacy and Safety of Ocrelizumab in Relapsing Multiple Sclerosis: Results of the Phase III, Interferon ß-1a-Controlled OPERA I and OPERA II Studies
Fred Lublin, MD, Icahn School of Medicine at Mount Sinai;
Douglas L Arnold, MD, NeuroRx Research;
Amit Bar-Or, MD, FRCPC, McGill University;
Giancarlo Comi, MD, University Vita-Salute San Raffaele;
Stephen L Hauser, MD, University of California;
Krzysztof Selmaj, MD, PhD, Medical University of Lodz;
Anthony Traboulsee, MD, FRCPC, University of British Columbia;
Peter Chin, MD, Genentech, Inc.;
Paulo Fontoura, MD, PhD, F. Hoffmann-La Roche Ltd.;
Hideki Garren, MD, PhD, F. Hoffmann-La Roche Ltd.;
Gaelle Klingelschmitt, MSc, F. Hoffmann-La Roche Ltd.;
Donna Masterman, MD, Genentech, Inc.;
Ludwig Kappos, MD, PhD, University Hospital Basel;
Hans-Peter Hartung, MD, FRCP, FAAN, FANA, Heinrich-Heine-University Düsseldorf;
Ashley J Porter, PhD, Articulate Science
Effect of Ocrelizumab on Clinical Disability in Two Identical Phase III, Double-Blind, Double-Dummy, Interferon ß-1a–Controlled Studies
Fred Lublin, MD, Icahn School of Medicine at Mount Sinai;
Douglas L Arnold, MD, NeuroRx Research;
Amit Bar-Or, MD, FRCPC, McGill University;
Giancarlo Comi, MD, University Vita-Salute San Raffaele;
Hans-Peter Hartung, MD, FRCP, FAAN, FANA, Heinrich-Heine-University Düsseldorf;
Stephen L Hauser, MD, University of California;
Krzysztof Selmaj, MD, PhD, Medical University of Lodz;
Anthony Traboulsee, MD, FRCPC, University of British Columbia;
Peter Chin, MD, Genentech, Inc.;
Paulo Fontoura, MD, PhD, F. Hoffmann-La Roche Ltd.;
Hideki Garren, MD, PhD, F. Hoffmann-La Roche Ltd.;
Gaelle Klingelschmitt, MSc, F. Hoffmann-La Roche Ltd.;
Donna Masterman, MD, Genentech, Inc.;
Ludwig Kappos, MD, PhD, University Hospital Basel;
Ashley J Porter, PhD, Articulate Science
Relapse Rates of Patients with Multiple Sclerosis Newly Initiating Subcutaneous Interferon ß-1a vs Oral Disease-Modifying Drugs in the Real World
Chris M Kozma, PhD, CK Consulting Associates, LLC;
Frederick Munschauer, MD, EMD Serono, Inc.;
Amy L Phillips, PharmD, EMD Serono, Inc.;
Michele Springer, BA, Caudex
Effect of Oral Fingolimod Treatment on Brain Volume Loss in Patients with Relapsing–Remitting Multiple Sclerosis Estimated Using Bayesian Methodology
Guosheng Yin, PhD, The University of Hong Kong;
Xiangyi Meng, PhD, Novartis Pharmaceuticals Corporation;
M. Zahur Islam, PhD, Novartis Pharmaceuticals Corporation;
Jeremy Bright, PhD, Oxford Pharmagenesis;
Terence Smith, PhD, Oxford Pharmagenesis
Brain Health: Time Matters in Multiple Sclerosis – Developmental Process and Objectives of International Consensus Policy Recommendations
Kathleen Costello, MS, ANP-BC, MSCN, National Multiple Sclerosis Society;
Helmut Butzkueven, MBBS, PhD, University of Melbourne;
Suhayl Dhib-Jalbut, MD, RUTGERS Robert Wood Johnson Medical School;
Jeremy Hobart, PhD FRCP, Plymouth University Peninsula Schools of Medicine and Dentistry;
Gisela Kobelt, PhD, European Health Economics;
George Pepper, ., Shift.ms;
Maria Pia Sormani, PhD, University of Genoa;
Christoph Thalheim, ., Patient Advocate in Multiple Sclerosis;
Anthony Traboulsee, MD, FRCPC, University of British Colombia;
Timothy Vollmer, MD, University of Colorado Denver;
Gavin Giovannoni, MBBCh, PhD, Queen Mary University London, Blizard Institute, Barts and The London School of Medicine and Dentistry;
Katharine Murkett, ., Oxford PharmaGenesis;
Heather Lang, DPhil, Oxford PharmaGenesis
Infusion-Related Reactions With Ocrelizumab in the Phase III Double-Blind, Double-Dummy, Interferon ß-1a-Controlled OPERA I and OPERA II Studies
Krzysztof Selmaj, MD, PhD, Medical University of Lodz;
Douglas L Arnold, MD, McGill University;
Amit Bar-Or, MD, FRCPC, McGill University;
Giancarlo Comi, MD, University Vita-Salute San Raffaele;
Hans-Peter Hartung, MD, FRCP, FAAN, FANA, Heinrich-Heine-University Düsseldorf;
Stephen L Hauser, MD, University of California;
Fred Lublin, MD, Icahn School of Medicine at Mount Sinai;
Anthony Traboulsee, MD, FRCPC, University of British Columbia;
Nicole Mairon, MD, F. Hoffmann-La Roche Ltd.;
Peter Chin, MD, Genentech, Inc.;
Paulo Fontoura, MD, PhD, F. Hoffmann-La Roche Ltd.;
Hideki Garren, MD, PhD, F. Hoffmann-La Roche Ltd.;
Gaelle Klingelschmitt, MSc, F. Hoffmann-La Roche Ltd.;
Donna Masterman, MD, Genentech, Inc.;
Ludwig Kappos, MD, PhD, University Hospital Basel;
Ashley J Porter, PhD, Articulate Science
A Phase III, Open-label Study to Evaluate the Effect of Ocrelizumab on Immune Responses in Patients With Relapsing Multiple Sclerosis
Laurie Millar, PhD, F. Hoffmann-La Roche Ltd.;
Carrie Li, PhD, F. Hoffmann-La Roche Ltd.;
Henry Bennett, BSc, F. Hoffmann-La Roche Ltd.;
Hideki Garren, MD, PhD, F. Hoffmann-La Roche Ltd.;
Ashley J Porter, PhD, Articulate Science
Incidence of Infusion-Associated Reactions Decreases with Subsequent Courses of Alemtuzumab: 5-Year Data from the Care-MS Extension Study
Lori Mayer, DNP, MSN, RN, MSCN, Central Texas Neurology Consultants;
Edward J. Fox, MD, PhD, Central Texas Neurology Consultants;
Christopher LaGanke, MD, North Central Neurology Associates;
Bhupendra Khatri, MD, Wheaton Franciscan Regional MS Center;
Ann D Bass, MD, Neurology Center of San Antonio;
David H Margolin, MD, PhD, Genzyme, a Sanofi company;
Linda Kasten, MA, PROMETRIKA, LLC;
Patricia A Pagnotta, ARNP, MSN, MSCN, CCRN, Neurology Associates, PA
Lymphopenia in Multiple Sclerosis Patients Treated with Delayed-Release Dimethyl Fumarate: Analysis of 2 Electronic Health Record Databases in the US
Madé Wenten, PhD, MPH, Biogen;
Teesta Soman, MD, MBA, Biogen;
Cathy Lally, MSPH, Biogen;
Maneesh Juneja, BSc, Biogen;
Susan Eaton, MSPH, MT (ASCP), Biogen;
Claudia Prada, MD, PhD, Biogen;
Anne Dilley, BA, MPH, PhD, Biogen;
Jim B Lewin, PharmD, Biogen
Alemtuzumab Causes Significant, Transient, Post-Infusion Thrombocytopenia and Other Non-Autoimmune Cytopenias Following Initial and Subsequent Courses
Roochi S Ghodasara, MD, Advanced Neurosciences Institute;
Madelyn B Rarick, BSN, Advanced Neurosciences Institute;
Miranda C Mosley, BS, Advanced Neurosciences Institute;
Rachel A Morgan, BA, Advanced Neurosciences Institute;
S.R. Sparrow Smith, BS, MA, Advanced Neurosciences Institute;
Laurel Kagan, NP, Advanced Neurosciences Institute;
Daniel Kantor, MD, NeuroNexus Center - Novel Pharmaceutics Institute;
Joy Derwenskus, DO, MS, Advanced Neurosciences Institute;
Samuel F. Hunter, MD, PhD, Advanced Neurosciences Institute;
Roochi S Ghodasara, MD, Advanced Neurosciences Institute
Key Results from PREFERMS: Real-World Patient Retention and Outcomes on Fingolimod Versus Platform Injectable Disease-Modifying Therapies in Early Relapsing–Remitting MS
Mark Cascione, MD, Tampa Neurology Associates, South Tampa Multiple Sclerosis Center;
Bruce AC Cree, MD, PhD, University of California San Francisco;
Daniel Wynn, MD, Consultants in Neurology MS Center;
Xiangyi Meng, PhD, Novartis Pharmaceuticals Corporation;
Lesley Schofield, PhD, Novartis Pharmaceuticals Corporation;
Nadia Tenenbaum, MD, Novartis Pharmaceuticals Corporation;
Jeremy Bright, PhD, Oxford Pharmagenesis;
Terence Smith, PhD, Oxford Pharmagenesis
Final Outcomes from the Teriflunomide TOWER Extension Study: Up to 6 Years of Follow-up (Core Plus Extension) in Patients with Relapsing Forms of MS
Mark S Freedman, MD, University of Ottawa and the Ottawa Hospital Research Institute;
Ludwig Kappos, MD, University Hospital Basel;
Giancarlo Comi, MD, University Vita-Salute San Raffaele;
Aaron E Miller, MD, Icahn School of Medicine at Mount Sinai;
Jerry Wolinsky, MD, University of Texas Health Science Center at Houston;
Karthinathan Thangavelu, PhD, Genzyme, a Sanofi company;
Philippe Truffinet, MD, Genzyme, a Sanofi company;
Myriam Benamor, MD, Genzyme, a Sanofi company;
Pascal Rufi, MD, Genzyme, a Sanofi company;
Paul O'Connor, MD, University of Toronto
JC Virus Antibody Seropositivity Index Decreases with Reduced Infusion Frequency in Natalizumab-Treated Multiple Sclerosis Patients
Michael A Mercurio, MD, Rush University Medical Center;
Michael Y Ko, MD, Rush University Medical Center;
Roumen Balabanov, MD, Rush University Multiple Sclerosis Center;
Jennifer A Strong, MS, Rush University Multiple Sclerosis Center;
Dusan Stefoski, MD, Rush University Medical Center
Real-World Comparison of Relapse Rates in Multiple Sclerosis Patients Treated with Disease-Modifying Therapies
Aaron Boster, MD, OhioHealth Neurological Physicians;
Jacqueline Nicholas, MD, MPH, Novartis Pharmaceutical Corporation;
Ning Wu, Ph.D., Biogen;
Wei-Shi Yeh, PhD, Biogen;
Monica A Fay, PharmD, Biogen;
Michael R Edwards, PhD, Biogen;
Ming-Yi Huang, PhD, Biogen;
Andrew Lee, PhD, Biogen;
Ming-Yi Huang, PhD, Biogen;
Jim B Lewin, PharmD, Biogen
Assessing the Incidence of Elevation in Eosinophils with the Use of Dimethyl Fumarate in Multiple Sclerosis
Demetrios Konstas, MD, University of South Florida;
Natalie K Moreo, MD, University of South Florida;
Chetan P Gandhy, MD, University of South Florida;
Michelle Lyman, MSII, University of South Florida College of Medicine;
Doris Deng, MSII, University of South Florida College of Medicine;
Robert Soares, BS, University of South Florida;
Steven Aradi, MD, University of Pennslyvania Perelman School of Medicine;
Derrick S Robertson, MD, University of South Florida;
Derrick Robertson, MD, University of South Florida
Assessing the Incidence of Lymphopenia with the Use of Dimethyl Fumarate in Multiple Sclerosis
Demetrios Konstas, MD, University of South Florida;
Natalie K Moreo, MD, University of South Florida;
Chetan P Gandhy, MD, University of South Florida;
Doris Deng, MSII, University of South Florida College of Medicine;
Michelle Lyman, MSII, University of South Florida College of Medicine;
Robert Soares, BS, University of South Florida;
Derrick S Robertson, MD, University of South Florida;
Derrick Robertson, MD, University of South Florida
The Use of Delayed-Release Dimethyl Fumarate in Routine Medical Practice in the Treatment of Multiple Sclerosis (ESTEEM): 6-Month Interim Analysis
Nicholas Everage, PhD, Biogen;
Claudia Prada, MD, PhD, Biogen;
Shifang Liu, PhD, Biogen;
Konstantin Balashov, MD, PhD, FAAN, Robert Wood Johnson Medical School;
Richard Macdonell, MD, FRACP, Austin Health, Univ. of Melbourne;
Jörg Windsheimer, MD, Praxis für Neurologie und Psychiatrie;
Kathryn Giles, MD, MSc, FRCPC, Cambridge Memorial Hospital;
Jim B Lewin, PharmD, Biogen
Open-Label Phase III Extension Studies to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab in Relapsing MS and Primary Progressive MS
Robert Kuhelj, PhD, F. Hoffmann-La Roche Ltd.;
Gurpreet Deol-Bhullar, BSc, OT, F. Hoffmann-La Roche Ltd.;
Monika Garas, PhD, F. Hoffmann-La Roche Ltd.;
Peter Chin, MD, Genentech, Inc.;
Stephen L Hauser, MD, University of California;
Xavier Montalban, MD, PhD, Hospital Vall d’Hebron University;
Ashley J Porter, PhD, Articulate Science
Serious Adverse Events, Autoimmunity, and Infections Following Alemtuzumab Therapy in a Large, High Disability, Treatment-Refractory MS Clinic Cohort
Roochi S Ghodasara, MD, Advanced Neurosciences Institute;
Miranda C Mosley, BS, Advanced Neurosciences Institute;
Rachel A Morgan, BA, Advanced Neurosciences Institute;
S.R. Sparrow Smith, BS, MA, Advanced Neurosciences Institute;
Madelyn B Rarick, BSN, Advanced Neurosciences Institute;
Laurel Kagan, NP, Advanced Neurosciences Institute;
Daniel Kantor, MD, Advanced Neurosciences Institute;
Joy Derwenskus, DO, MS, Advanced Neurosciences Institute;
Samuel F. Hunter, MD, PhD, NeuroNexus Center - Novel Pharmaceutics Institute;
Roochi S Ghodasara, MD, Advanced Neurosciences Institute
Long-Term Effect of Fingolimod on Disability: A Categorical Trend Analysis over 8 Years
Shannon Ritter, MS, Novartis Pharmaceuticals Corporation;
Anthony T Reder, MD, University of Chicago;
Daniela Piani Meier, PhD, Novartis Pharma AG;
Davorka Tomic, PhD, Novartis Pharma AG;
Bruce AC Cree, MD, PhD, University of California San Francisco;
Jeremy Bright, PhD, Oxford Pharmagenesis;
Terence Smith, PhD, Oxford Pharmagenesis
Alemtuzumab Infusion Experience
Tania A Reyna, MD, Oklahoma Medical Research Foundation;
Tony Sharp, PA, Oklahoma Medical Research Foundation;
Cecilie Fjeldstad, PhD, Oklahoma Medical Research Foundation;
Jennifer Smith, PA, Oklahoma Medical Research Foundation;
Gabriel Pardo, MD, Oklahoma Medical Research Foundation;
Tania A Reyna, MD, Oklahoma Medical Research Foundation
Treatment Adherence, Persistence, and Compliance at 96 Weeks in MS Patients Using Rebismart® for Injection of Interferon β-1a
Virginia Devonshire, MD, University of British Columbia;
Anthony Feinstein, MPhil, PhD, FRCP, University of Toronto, Sunnybrook Health Sciences Centre;
Alan Gillett, PhD, EMD Serono;
Virginia Devonshire, MD, University of British Columbia
Infusion-Related Reactions in the Phase III Double-Blind, Placebo-Controlled ORATORIO Study of Ocrelizumab in Primary Progressive Multiple Sclerosis
Xavier Montalban, MD, PhD, Vall d'Hebron University Hospital;
Douglas L Arnold, MD, McGill University;
Amit Bar-Or, MD, FRCPC, McGill University;
Jérôme de Seze, MD, PhD, University Hospital of Strasbourg;
Gavin Giovannoni, MBBCh, PhD, FCP (Neurol., SA), FRCP, FRCPath, Queen Mary University of London;
Bernhard Hemmer, MD, Munich Cluster for Systems Neurology (SyNergy);
Kottil Rammohan, MD, University of Miami;
Nicole Mairon, MD, F. Hoffmann-La Roche Ltd.;
Peter Chin, MD, Genentech, Inc.;
Paulo Fontoura, MD, PhD, F. Hoffmann-La Roche Ltd.;
Hideki Garren, MD, PhD, F. Hoffmann-La Roche Ltd.;
Donna Masterman, MD, Genentech, Inc.;
Annette Sauter, MD, F. Hoffmann-La Roche Ltd.;
Jerry Wolinsky, MD, University of Texas Health Science Center at Houston;
Ashley J Porter, PhD, Articulate Science
Cuprizone Mouse Model of Demyelination: Environmental Enhancement Reverses Cognitive Deficits
Zahra Almosawi, BSc, College of Medicine and Medical Sciences, Arabian Gulf University;
Amal Almahroos, Bsc, College of Medicine and Medical Sciences, Arabian Gulf University;
Reem Abdulla, Bsc, College of Medicine and Medical Sciences, Arabian Gulf University;
Ayman Mohamed, BSc, College of Medicine and Medical Sciences, Arabian Gulf University;
Hawra Alalwan, BSc, College of Medicine and Medical Sciences, Arabian Gulf University;
Ahmmed Almubarak, BSc, College of Medicine and Medical Sciences, Arabian Gulf University;
Fajer Alammadi, BSc, College of Medicine and Medical Sciences, Arabian Gulf University;
Amer Kamal, Professor, College of Medicine and Medical Sciences, Arabian Gulf University;
Ahmed Al-Mahrezi, BSc, College of Medicine and Medical Sciences, Arabian Gulf University
